There are no licensed vaccines available against Moraxella catarrhalis, a significant human respiratory pathogen. Lipooligosaccharide (LOS) based conjugate vaccines derived from individual serotype M. catarrhalis only showed partial protection coverage. A vaccine combining LOS conjugates of two or three serotypes might provide a broader protection.
Mice were immunized intranasally with the combined conjugates consisting of LOS from serotype A and B or serotype A, B, and C followed by challenge with different M. catarrhalis strains of three serotypes. Mouse lungs, nasal washes, and sera were collected after each challenge for bacterial counts, histological evaluation, cytokine profiles, antibody level and binding activity determinations.
Intranasal administration of the combined LOS conjugates not only enhanced pulmonary bacterial clearance of all three serotypes of M. catarrhalis strains in vaccinated mice, but also elevated serotype-specific anti-LOS immunoglobulin (Ig)A and IgG titers in nasal wash and serum respectively. Mice vaccinated with the combined LOS conjugates also showed increased interferon (IFN)-γ, interleukin (IL)-12, and IL-4 in the lungs after challenges. Compared to the control group, mice immunized with the combined LOS conjugates also showed reduced lung inflammation after M. catarrhalis infections. The hyperimmune sera induced by the combined conjugates exhibited a broad cross-reactivity toward all three serotypes of M. catarrhalis under transmission electron microscopy.
The combined vaccine of serotype A and B LOS conjugates provides protection against most M. catarrhalis strains by eliciting humoral and cellular immune responses.
Citation: Ren D, Xie H, Zhang W, Hassan F, Petralia RS, Yu S, et al. (2011) Intranasal Immunization of the Combined Lipooligosaccharide Conjugates Protects Mice from the Challenges with Three Serotypes of Moraxella catarrhalis. PLoS ONE 6(12): e29553. doi:10.1371/journal.pone.0029553
Editor: Ray Borrow, Health Protection Agency, United Kingdom
Received: August 1, 2011; Accepted: November 30, 2011; Published: December 22, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This research was supported by the Intramural Research Program of the National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH), United States of America (#NIH0010103632). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Moraxella catarrhalis is a Gram-negative aerobic diplococcus that causes respiratory illness exclusively in humans. It is responsible for 10% – 20% of all episodes of otitis media in infants and children , . Approximately 80% of children experience at least one episode of otitis media by the age of 3 years . Otitis media accounts for 24.5 million physician visits, more than 13 million antibiotic prescriptions, and approximately $6 billion in health care costs in the United States annually , . In addition, M. catarrhalis is also responsible for an estimated 2 – 4 million exacerbations of chronic obstructive pulmonary disease (COPD) in the elderly annually . Prevention of M. catarrhalis infections by effective vaccination thus would potentially have a significant impact on both public health and the economy.
However, there is no licensed vaccine for M. catarrhalis except that a number of M. catarrhalis vaccine candidates are under development or clinical testing –. Most of these vaccine candidates are designed to target adhesion molecules in the outer membrane of M. catarrhalis such as M. catarrhalis immunoglobulin D-binding protein (MID) , the ubiquitous surface protein A (UspA) , and catarrhalis outer membrane protein B (CopB) . Although these outer membrane protein-based vaccine candidates are immunogenic, their efficiency is limited by antigenic heterogeneity . The lipooligosaccharide (LOS) is the carbohydrate structure in the outer membrane of M. catarrhalis. Being a major virulence factor of M. catarrhalis, LOS induces excessive inflammation via a Toll-like receptor 4 (TLR4) and CD14 dependent pathway . The structures of LOS are conserved among 95% of known M. catarrhalis strains and clinical isolates , . Based on the LOS structures (Figure 1) –, M. catarrhalis can be categorized into three serotypes: A, B, and C accounting for 61.3%, 28.8%, and 5.3% of the 302 strains tested . Monoclonal antibodies specific for serotype A LOS have been reported to cross-react with serotype C LOS . We have shown that M. catarrhalis LOS-based conjugate vaccine candidates from three individual serotypes were immunogenic in vivo, but were only able to elicit bactericidal activity toward a portion of M. catarrhalis strains and clinical isolates –. Immunization with a LOS conjugate derived from serotype A protects against homologous and heterologous challenges including serotype A strains and a serotype C strain but not a serotype B strain in a mouse pulmonary clearance model , . Similarly, immunization with a LOS conjugate derived from serotype B or C alone has been shown to protect against only partial M. catarrhalis strains in our preliminary mouse pulmonary clearance study.
Three main serotypes, A, B and C, are presented with different R groups –. Abbreviations: Gal, galactose; Kdo, 3-deoxy-D-manno-octulosonic acid; Glc, glucose; GlcNAc, N-acetyl-D-glucosamine; p, pyranose.
Based on these findings, we hypothesized that a combination of LOS conjugates from two or three serotypes would protect against most M. catarrhalis strains. To test this, we vaccinated mice with the combined M. catarrhalis LOS conjugates consisting of serotype A and B or serotype A, B, and C via intranasal route. The protection elicited by the combined LOS conjugates against homologous and heterologous strains of M. catarrhalis was evaluated in a mouse pulmonary clearance model. Our primary goal was to determine the optimal conjugate combination with the maximum protection against all three serotypes of M. catarrhalis in mice.
Materials and Methods
All experiments involving mice were performed according to the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Protocols were reviewed and approved by institutional review boards at the National Institutes of Health (Permit Number: 1158).
M. catarrhalis strain O35E (serotype A) was kindly provided by Eric J. Hansen (the University of Texas, Dallas, TX) and strain 25238 (serotype A) was purchased from the American Type Culture Collection (Manassas, VA). M. catarrhalis serotype B strains 26397 and 26400, and serotype C strains 26404 and 26391 were obtained from the Culture Collection of the University of Goteborg, Department of Clinical Bacteriology, Goteborg, Sweden.
Purification of LOSs from prototype strains 25238 (A), 26397 (B), and 26404 (C), detoxification of the LOSs, and conjugation of detoxified LOSs (dLOSs) to the carrier tetanus toxoid (TT) were performed for each serotype LOS individually as described –. The synthesized dLOS-TT from 25238, 26397, or 26404 was designated as conjugate A, B, or C, respectively. The composition of the conjugates is described in Table 1. The combination of conjugate A physically mixed with conjugate B in the equal amount and the combination of conjugate A physically mixed with conjugate B and conjugate C in the equal amount were named as conjugates AB and ABC, respectively.
Six to 8 weeks old female BALB/c mice were obtained from Taconic Farms Inc. (Germantown, NY). Cholera toxin (List Biological Laboratories, Campbell, CA) was used as the mucosal adjuvant at 1 µg/dose/mouse either alone or in the combination with conjugates AB, or conjugates ABC (2.5 µg of each carbohydrate per dose per mouse). Mice (8 – 10 per group) were anesthetized intraperitoneally with 0.1 ml of 2% ketamine (Fort Dodge Laboratories, Inc., Fort Dodge, IA) and 0.2% xylazine (Miles Inc., Shawnee Mission, KS) in 0.9% NaCl. A total of 18 µl of each vaccine preparation was slowly instilled through a micropipette into both nares of each mouse. Mice were immunized weekly for a total of 4 weeks.
Bacterial challenge and sampling
One week after the last booster, mice were challenged with aerosolized M. catarrhalis strains 25238 (A), O35E (A), 26397 (B), 26400 (B), 26404 (C), or 26391 (C) at 5×108 to 1×109 CFU/ml in an inhalation exposure system (Glas-Col, LLC, Terre Haute, IN) as described . At 6 h post-challenge, mice were euthanized. Sera and nasal washes were collected for antibody detection. A subset of mouse lungs were harvested and homogenized in 1 ml of phosphate buffered saline (PBS) with a Precellys 24 homogenizer (Bertin Technologies, Paris, France). Serially diluted lung homogenates were cultured on chocolate agar plates overnight at 37°C with 5% CO2 to determine colony forming unit (CFU) counts. The rest of lung homogenates were then frozen for cytokine profiles. Another subset of mouse lungs were harvested and fixed in 10% neutral formaldehyde for histological assessment.
Enzyme-linked immunosorbent assay (ELISA)
The 96-well plates were coated with LOS of strains 25238 (A), 26397 (B), or 26404 (C) at 10 µg/ml. The anti-LOS specific IgA in nasal washes and IgG in sera were determined by ELISA as described  and were expressed as the reciprocal of the highest serum dilution. Specific mouse hyperimmune sera against the whole cells of strain 25238 (A), 26397 (B), or 26404 (C) were used as references –.
The inflammatory cytokines including interferon (IFN)-γ, interleukin (IL)-12 (total), IL-4, tumor necrosis factor (TNF)-α, and mouse keratinocyte chemoattractant (mKC) in the lung homogenates following challenges were quantified using a mouse TH1/TH2 9-Plex Assay Ultra-Sensitive Kit according to the manufacturer's instructions and analyzed in a SECTOR imager 2400 (Meso Scale Discovery, Gaithersburg, MD).
Fixed mouse lungs were embedded in paraffin, sectioned, mounted on slides, and stained with hematoxylin and eosin (H&E). The slides were then observed and imaged under an Olympus IX71 microscope with a digital camera (Olympus America Inc., Miami, FL). Lung sections were scored for lung injury, including the following: (1) intra-alveolar infiltration of inflammatory cells, (2) thickness of the alveolar wall, (3) alveolar hemorrhage, and (4) intra-alveolar proteinaceous exudate. The items were semi-quantitatively scored as none, minimal, light, moderate, or severe (score 0, 1, 2, 3, or 4, respectively) by a pathologist blinded to the experimental groups. The combined score of all four parameters was taken for each field. Ten randomly chosen fields from each animal with approximately the same number of alveoli were analyzed on each slide at ×400 magnification. The lung injury score was obtained by averaging the scores of all the fields from each animal and 6 mice per group were inspected.
Immunoelectron microscopy of bacteria
Formvar-coated 200-mesh grids (Electron Microscopy Sciences, Hatfield, PA) were floated on the suspension of strain 25238 (A), 26397 (B), or 26404 (C) in PBS and blotted dry. Grids were then incubated with sera from mice intranasally immunized with the combined conjugates AB or the corresponding pre-immune sera (1:400 dilution in PBS with 0.5% BSA) at room temperature for 30 min. Subsequently, the grids were incubated with gold (5-nm diameter)-conjugated goat anti-mouse IgG (Ted Pella, Inc., Redding, CA, 1:20 dilution in PBS with 0.5% BSA) for 60 min. The grids were blotted and washed 3 times with PBS between steps. The bacteria were then negatively stained with a mixture of equal volumes of 2% ammonium acetate and 2% ammonium molybdate (Sigma, St. Louis, MO). The grids were viewed under a JEOL JEM-1010 transmission electron microscope (JEOL Ltd., Tokyo, Japan).
The geometric mean (GM) of the anti-LOS specific IgA and IgG titers from n independent observations plus/minus (±) standard deviations (SD) were determined. The pulmonary levels of viable residual bacteria counts were logarithm transformed ((log)10 CFU) before being subjected to one-way analysis of variance (ANOVA). The differences in the lung cytokines and the differences in the pathological lung injury scores among different groups were determined by ANOVA. A P value less than 0.05 was considered significant. A nonparametric Spearman correlation test was employed to analyze the correlations among the residual bacterial counts, antibodies, and pulmonary cytokine levels.
Bacterial clearance in the mouse lungs
Figure 2 shows the pulmonary bacterial clearance in immunized mice after challenge with different M. catarrhalis strains (Fig. 2). Compared to adjuvant immunized control group, intranasal vaccination with the combined conjugates AB or ABC plus adjuvant significantly reduced the pulmonary bacterial burdens by 84% – 96% in immunized mice following challenges with three serotypes of M. catarrhalis (Fig. 2). However, the addition of conjugate C in the vaccine mixture showed no obvious benefit in pulmonary clearance of M. catarrhalis including serotype C strains when compared to the mice receiving only the combined conjugates AB (Fig. 2).
Mice (8 – 10 per group) were vaccinated intranasally (1 dose per week, 4 doses in total) with either the adjuvant cholera toxin alone (1 µg/dose/mouse) or the combined conjugates AB or ABC (2.5 µg of each carbohydrate per dose per mouse) plus adjuvant. One week after the last booster, mice were challenged with aerosolized M. catarrhalis including 25238 (type A), O35E (type A), 26397 (type B), 26400 (type B), 26404 (type C), or 26391 (type C) (5×108 to 1×109 CFU/ml). Mouse lungs were harvested at 6 h after the challenge for bacterial counts. The viable bacteria are expressed as the mean of CFUs ± standard error of the mean (SEM). *P<0.05 indicates the significant difference vs adjuvant control by ANOVA.
Mucosal and systemic antibody responses
Intranasal immunization of the combined LOS conjugates plus adjuvant significantly increased anti-M. catarrhalis LOS serotype-specific IgA levels in nasal wash (conjugates AB plus adjuvant vs adjuvant alone: 2.8 – 7.7 folds; conjugates ABC plus adjuvant vs adjuvant alone: 5.4 – 28.4 folds) following challenges (Table 2). Furthermore, intranasal administration of the combined LOS conjugates plus adjuvant also enhanced serotype-specific IgG levels in serum (conjugates AB plus adjuvant vs adjuvant alone: 2.9 – 10.0 folds; conjugates ABC plus adjuvant vs adjuvant alone: 8.6 – 34.1 folds). The higher levels of nasal IgA and serum IgG produced, the lower levels of viable bacteria recovered in the lungs of the vaccinated mice following challenges with all three serotypes of M. catarrhalis strains (r = −0.3532, P<0.0001 for nasal IgA; r = −0.4195, P<0.0001 for serum IgG). In general, administration of the combined conjugates ABC elicited higher levels of anti-M. catarrhalis LOS specific IgA in nasal wash and IgG in serum than the combined conjugates AB (Table 2).
Pulmonary cytokine secretion after challenges
Following challenges with three serotypes of M. catarrahlis strains, the pulmonary levels of IFN-γ, IL-12, and IL-4 were dramatically elevated in the mice receiving the intranasal vaccination of the combined LOS conjugates plus adjuvant (Fig. 3A, 3B, and 3C). Meanwhile, the levels of mKC and TNF-α in the same lung homogenates were also significantly reduced when compared to adjuvant administered controls (Fig. 3D and 3E). The elevated pulmonary IFN-γ, IL-12, and IL-4 levels positively correlated with the increased nasal wash IgA titers (r = 0.2152, P<0.01 for IFN-γ; r = 0.3060, P<0.001 for IL-12) and serum IgG titers (r = 0.3034, P<0. 001 for IFN-γ; r = 0.3707, P<0.0001 for IL-12; r = 0.2032, P<0.05 for IL-4) in mice that had been immunized with the combined conjugates AB or ABC plus adjuvant. Moreover, the reduced pulmonary levels of inflammatory mKC and TNF-α also significantly correlated with the decreased bacterial recovery in the same lung homogenates of the mice receiving the combined LOS conjugates plus adjuvant (r = 0.6380, P<0.0001 for mKC; r = 0.6239, P<0.0001 for TNF-α).
Mice were vaccinated (1 dose per week, 4 doses in total) with either the adjuvant cholera toxin alone (1 µg/dose/mouse) or the combined conjugates AB or ABC (2.5 µg of each carbohydrate per dose per mouse) plus adjuvant. One week after the last booster, mice were challenged with aerosolized M. catarrhalis including 25238 (type A), O35E (type A), 26397 (type B), 26400 (type B), 26404 (type C), or 26391 (type C) (5×108 to 1×109 CFU/ml). At 6 h after the challenge, mouse lungs were harvested and homogenized for detection of IFN-γ, IL-12, IL-4, mKC, and TNF-α. Data are presented as mean ± SEM. *P<0.05 indicates the significant difference vs adjuvant control by ANOVA. Note: Pulmonary IL-4 in mice immunized with adjuvant only was below the detection limit after M. catarrhalis 26391 challenge.
Histological changes in the lungs of vaccinated mice after challenges
Unlike the normal mouse lung architecture (Fig. 4A), the lungs of the adjuvant alone administered mice exhibited prominent infiltration of neutrophils and macrophages after M. catarrhalis challenges (Fig. 4B). However, the M. catarrhalis induced pulmonary infiltration of inflammatory cells was diminished in the mice that had been vaccinated with the combined conjugates AB plus adjuvant (Fig. 4C). Consistently, the adjuvant alone immunized mice displayed severe lung injury when compared to naive mice (P<0.05) (Fig. 4D). On the contrary, vaccination with the combined conjugates AB plus adjuvant significantly reduced the score of acute lung injury in mice (P<0.05 vs adjuvant alone, Fig. 4D) following M. catarrhalis challenges. In addition, a robust lymphoproliferation along with the formation of focally propagated lymphocytes were observed in the subepithelia of trachea and bronchi of the mice immunized with the conjugates AB plus adjuvant followed by M. catarrhalis challenges (Fig. 4C). In contrast, the lymphocytic proliferation was not found in the lungs of naive mice and the lungs of adjuvant only immunized mice after the challenges (Fig. 4A and 4B). The mice vaccinated with the conjugates ABC plus adjuvant showed the similar lung histological changes as those of the mice receiving the conjugates AB plus adjuvant after M. catarrhalis challenges (data not shown).
Mice were vaccinated intranasally (1 dose per week, 4 doses in total) with either the adjuvant cholera toxin alone (1 µg/dose/mouse) or the combined conjugates AB (2.5 µg of each carbohydrate per dose per mouse) plus adjuvant. One week after the last booster, mice were challenged with aerosolized M. catarrhalis. Mouse lungs were harvested 6 h later for H&E staining. (A) Normal lung of a naive mouse; (B) Lung of the mouse administered with adjuvant only; (C) Lung of the mouse vaccinated with the combined conjugates AB plus adjuvant. Arrows and arrowheads show infiltrating neutrophils and macrophages, respectively, in inflamed lungs of mice after challenge by M. catarrhalis strains. Double arrowheads show proliferating lymphocytes in the lungs of conjugate-immunized mice after challenge by M. catarrhalis strains. Original magnification ×100; ×400 (insets). (D) Histopathological lung injury scores for mice receiving either the adjuvant only or the combined conjugates AB plus adjuvant followed with M. catarrhalis challenges. The scores were obtained from 10 random fields per mouse and 6 mice per group at magnification ×400. The categories used to generate the score were intra-alveolar infiltrates, alveolar septal thickeness, alveolar hemorrhage, and intra-alveolar proteinaceous exudates. Data are expressed as mean ± SD. *P<0.05 or #P<0.05 indicates the significant difference vs naive mice or adjuvant only administered mice by ANOVA, respectively.
Immunoelectron microscopy of M. catarrhalis
The cross-reactivity of anti-M. catarrhalis LOS specific hyperimmune mouse sera generated by vaccination with the combined conjugates AB plus adjuvant were further characterized by immunoelectron microscopy. As shown in Fig. 5, electron-dense gold particles clearly scattered across the surfaces of all three serotypes of M. catarrhalis strains including 25238 (type A, Fig. 5A), 26397 (type B, Fig. 5B), and 26404 (type C, Fig. 5C) after pre-incubation with the hyperimmune sera of mice vaccinated with the combined conjugates AB plus adjuvant. In contrast, the whole cells of 25238 pre-incubated with the corresponding mouse pre-immune sera showed no binding of gold particles on the surface (Fig. 5D).
Mice were vaccinated intranasally (1 dose per week, 4 doses in total) with either the adjuvant cholera toxin alone (1 μg/dose/mouse) or the combined conjugates AB (2.5 µg of each carbohydrate per dose per mouse) plus adjuvant. Mouse sera were collected at 1 week after the final immunization. Whole cells of strain 25238 (type A, A), 26397 (type B, B), or 26404 (type C, C) were incubated with the mouse hyperimmune sera (1:400 dilution) followed by gold (5-nm diameter)-conjugated goat anti-mouse IgG. Whole cells of strain 25238 (D) incubated with the corresponding pre-immune mouse sera (1:400 dilution) were included as a control. Scale bar, 100 nm.
LOS is a major virulence factor located in the outer membrane of M. catarrhalis. It can potentially induce excessive inflammation via cellular cross-talk . Unlike the outer membrane proteins such as MID, UspA, and CopB that show a great plasticity in their antigenicity , , the structures of LOS are highly conserved within each of the three serotypes of M. catarrhalis , . Thus LOS has the great potential to be developed into carbohydrate-based conjugate vaccines against M. catarrhalis infections. Previously we have reported that LOS based conjugate vaccines derived from individual serotypes of M. catarrhalis were highly immunogenic in vivo, but could protect against only a fraction of M. catarrhalis strains –. Hence, we hypothesized that a combination of LOS conjugates of two or three serotypes could provide a broader protection against most of the known M. catarrhalis strains.
In the present study, we demonstrated that intranasal immunization of the combined LOS conjugates from serotype A and B or from serotype A, B, and C led to a significant reduction in the bacterial burden in the lungs of M. catarrhalis infected mice. Mice vaccinated with the combined LOS conjugates not only efficiently cleared M. catarrhalis of the same serotype out of the respiratory system but also the strains of different serotypes. Interestingly, both the combined LOS conjugates AB and ABC demonstrated a similar efficiency in clearing not only serotype A and B strains but also serotype C bacteria. This is not surprising since there is a high cross-reactivity in the antibodies against the LOS structures between serotype A and C strains . Serotype A and B M. catarrhalis are the major clinical isolates and serotype C comprises less than 6% of M. catarrhalis strains identified so far. The supplement of serotype C conjugate into conjugates AB combination may induce additional homologous or cross-reactive heterologous antibodies against each serotype LOS antigen. Therefore, the mice receiving the ABC conjugates generally showed higher levels of serum IgG and nasal IgA responses than the mice administered with the AB conjugates. However, our results indicated that intranasal vaccination with the combined conjugates consisting of serotype A and B LOS was efficient to combat the tested M. catarrhalis strains of all three serotypes. The addition of serotype C conjugate into the conjugates AB combination did not further enhance the efficiency of pulmonary bacterial clearance in the current study. Our results also suggest that the combined LOS conjugates AB could be a potent and cost-effective mucosal vaccine candidate to fight against M. catarrhalis infections.
As revealed by the histology data, intranasal immunization of the combined LOS conjugates also resulted in a robust proliferation of mucosal lymphocytes in the airway branches in vaccinated mice. These mucosal lymphocytes could potentially differentiate into polymeric IgA (pIgA)-producing plasma cells and produce secretory IgA (SIgA) , . Anti-antigen specific SIgA could enhance adherence of bacteria to mucus, thereby promoting clearance by respiratory ciliary movement . SIgA can also inhibit bacterial agglutination, adherence for epithelial colonization and penetration for invasion . In addition to elevated mucosal IgA secretion, intranasal immunization of the combined LOS conjugates also significantly increased anti-antigen specific serum IgG. The induced anti-LOS specific serum IgG demonstrated a broad cross-reactivity toward all three prototypes of M. catarrhalis strains under electron microscopy. Highly cross-reactive serum IgG might extravasate into the infected respiratory mucosal surface, promote phagocytosis of M. catarrhalis by alveolar macrophages and infiltrating neutrophils, and facilitate bacterial clearance by complement-mediated killing .
In addition to humoral responses, intranasal immunization of the combined LOS conjugates also stimulated anti-antigen specific cell-mediated immune responses in the lungs of vaccinated mice. Pulmonary augmentation of Th1 type cytokines IFN-γ and IL-12 could promote phagocytosis and respiratory burst thus leading to killing of M. catarrhalis . IFN-γ could also induce the antibody isotype µ→γ2α switch and result in IgG2a antibody production that could potentially enhance bacterial clearance by complement-mediated cytotoxicity , . Similarly, pulmonary IL-4, a typical Th2 type cytokine was also significantly increased in the combined conjugates vaccinated mice following challenges. IL-4 is pivotal in B-cell switching from secretory IgM (SIgM) to IgG1 subclass production and promotes IgG1, IgG2b, and IgA responses in mice . The augmentation of IL-4 has been linked to enhanced M. catarrhalis clearance from mouse lungs . In our present study, enhanced pulmonary Th1 and Th2 cytokines not only correlated significantly with increased lung clearance of M. catarrhalis, but also correlated well with elevated mucosal IgA and serum IgG titers.
Moreover, intranasal immunization of the combined LOS conjugates plus adjuvant also resulted in significantly less pro-inflammatory cytokines such as TNF-α and mKC in the lungs of vaccinated mice after M. catarrhalis infections than those administered with adjuvant only. The reduced pro-inflammatory TNF-α and mKC correlated significantly with enhanced pulmonary clearance of M. catarrhalis, suggesting vaccination of the combined LOS conjugates could reduce M. catarrhalis induced pulmonary inflammation. This was consistent with the histology data showing that the combined conjugates vaccinated mouse lung structures were more like those of the normal mouse lung.
In summary, intranasal vaccination with the combined conjugates consisting of LOS from serotype A and B could efficiently protect mice from the challenges of tested M. catarrhalis strains of all three serotypes.
We are grateful to Dr. Eric J. Hansen at the University of Texas, Dallas, TX for providing M. catarrhalis O35E and to John C. McMichael (retired from Wyeth Vaccines, New York, NY) for providing M. catarrhalis LOSs. We thank the NIH Fellows Editorial Board, Drs. David Robinson (NIDCD/NIH, Rockville, MD), Gang Dong (NIAID/NIH, Bethesda, MD), and Wei-Gang Hu (Defense Research & Development Canada-Suffield, Medicine Hat, AB, Canada) for their review and comments during the preparation of this manuscript.
Conceived and designed the experiments: X-XG DR HX. Performed the experiments: DR HX WZ FH RSP X-XG. Analyzed the data: DR HX X-XG. Contributed reagents/materials/analysis tools: X-XG HX RSP SY DJL. Wrote the paper: DR HX X-XG.
- 1. Murphy TF, Parameswaran GI (2009) Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 49: 124–131.
- 2. Murphy TF, Brauer AL, Grant BJ, Sethi S (2005) Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 172: 195–199.
- 3. Klein JO (1994) Otitis media. Clin Infect Dis 19: 823–833.
- 4. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media (2004) Diagnosis and management of acute otitis media. Pediatrics 113: 1451–1465.
- 5. McMichael JC (2000) Vaccines for Moraxella catarrhalis. Vaccine 19: Suppl 1S101–107.
- 6. Tan TT, Riesbeck K (2007) Current progress of adhesins as vaccine candidates for Moraxella catarrhalis. Expert Rev Vaccines 6: 949–956.
- 7. Mawas F, Ho MM, Corbel MJ (2009) Current progress with Moraxella catarrhalis antigens as vaccine candidates. Expert Rev Vaccines 8: 77–90.
- 8. Tan TT, Christensen JJ, Dziegiel MH, Forsgren A, Riesbeck K (2006) Comparison of the serological responses to Moraxella catarrhalis immunoglobulin D-binding outer membrane protein and the ubiquitous surface proteins A1 and A2. Infect Immun 74: 6377–6386.
- 9. Chen D, McMichael JC, VanDerMeid KR, Hahn D, Mininni T, et al. (1996) Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect Immun 64: 1900–1905.
- 10. Aebi C, Cope LD, Latimer JL, Thomas SE, Slaughter CA, et al. (1998) Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis. Infect Immun 66: 540–548.
- 11. Xie H, Gu XX (2008) Moraxella catarrhalis lipooligosaccharide selectively upregulates ICAM-1 expression on human monocytes and stimulates adjacent naive monocytes to produce TNF-alpha through cellular cross-talk. Cell Microbiol 10: 1453–1467.
- 12. Vaneechoutte M, Verschraegen G, Claeys G, Van Den Abeele AM (1990) Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens. J Clin Microbiol 28: 182–187.
- 13. Rahman M, Jonsson AB, Holme T (1998) Monoclonal antibodies to the epitope alpha-Gal-(1-4)-beta-Gal-(1- of Moraxella catarrhalis LPS react with a similar epitope in type IV pili of Neisseria meningitidis. Microb Pathog 24: 299–308.
- 14. Edebrink P, Jansson PE, Rahman MM, Widmalm G, Holme T, et al. (1994) Structural studies of the O-polysaccharide from the lipopolysaccharide of Moraxella (Branhamella) catarrhalis serotype A (strain ATCC 25238). Carbohydr Res 257: 269–284.
- 15. Edebrink P, Jansson PE, Widmalm G, Holme T, Rahman M (1996) The structures of oligosaccharides isolated from the lipopolysaccharide of Moraxella catarrhalis serotype B, strain CCUG 3292. Carbohydr Res 295: 127–146.
- 16. Edebrink P, Jansson PE, Rahman MM, Widmalm G, Holme T, et al. (1995) Structural studies of the O-antigen oligosaccharides from two strains of Moraxella catarrhalis serotype C. Carbohydr Res 266: 237–261.
- 17. Gu XX, Chen J, Barenkamp SJ, Robbins JB, Tsai CM, et al. (1998) Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect Immun 66: 1891–1897.
- 18. Yu S, Gu XX (2005) Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis. Infect Immun 73: 2790–2796.
- 19. Yu S, Gu XX (2007) Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis. Infect Immun 75: 2974–2980.
- 20. Jiao X, Hirano T, Hou Y, Gu XX (2002) Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect Immun 70: 5982–5989.
- 21. Hu WG, Chen J, Battey JF, Gu XX (2000) Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins. Infect Immun 68: 4980–4985.
- 22. Hu WG, Chen J, Collins FM, Gu XX (1999) An aerosol challenge mouse model for Moraxella catarrhalis. Vaccine 18: 799–804.
- 23. McMichael JC (2000) Progress toward the development of a vaccine to prevent Moraxella (Branhamella) catarrhalis infections. Microbes Infect 2: 561–568.
- 24. Brandtzaeg P (2003) Role of secretory antibodies in the defence against infections. Int J Med Microbiol 293: 3–15.
- 25. Lee CJ, Lee LH, Gu XX (2005) Mucosal immunity induced by pneumococcal glycoconjugate. Crit Rev Microbiol 31: 137–144.
- 26. Goldblum RM, Hanson LÅ, Brandtzaeg P (1996) The mucosal defense system. In: Stiehm ER, editor. Immunologic Disorders in Infants and Children. 4th ed. Philadelphia, , PA: W. B. Saunders Co. pp. 159–199.
- 27. Murphy S, Florman AL (1983) Lung defenses against infection: a clinical correlation. Pediatrics 72: 1–15.
- 28. Welsh DA, Mason CM (2001) Host defense in respiratory infections. Med Clin North Am 85: 1329–1347.
- 29. McGhee JR, Czerkinsky C, Mesteckey J (1999) Mucosal vaccines: an overview. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, et al., editors. Mucosal immunology. 2nd ed. San Diego, , CA: Academic Press. pp. 741–757.
- 30. Oishi K, Koles NL, Guelde G, Pollack M (1992) Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis 165: 34–45.